Cellectar Biosciences, Inc. announced the appointment of Mr. Dov Elefant, a seasoned biotechnology executive, as its Chief Financial Officer effective as of September 10, 2019. Mr. Dov Elefant is an established executive with over 20 years of industry experience in corporate finance and operational leadership positions. Mr. Elefant joins Cellectar after having served as Chief Financial Officer at several companies, most recently at Akari Therapeutics, where he helped raise nearly $100 million during his tenure. Prior to Akari, he served as Chief Financial Officer at Celsus Therapeutics until its merger in September 2015, and at Althera Medical Ltd. Mr. Elefant has also been a consultant for a number of companies and was the Corporate Controller at Lev Pharmaceuticals through its acquisition by ViroPharma.